Bristol Myers Squibb stock heads into the open after a 0.8 percent gain
Published on 09/21/2026 at 08:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, marking a 0.8 percent gain for the session in United States dollars. Per exchange data, the shares traded between an intraday low of USD 62.19 and a high of USD 63.06, with the closing price matching the session high and leaving the stock in the middle of its 52-week range from USD 42.53 to USD 68.64.
September 18, 2026 in numbers
Bristol Myers Squibb Co. (ISIN US1101221083) recorded a close at USD 63.06 on the New York Stock Exchange on September 18, 2026, after moving within a day range of USD 62.19 to USD 63.06 and ending at the session high. Data compiled by Forbes as of September 18, 2026 indicated that trading volume reached 36,576,219 shares, underscoring active interest in the name during the session.Ad-hoc-news reported that the stock remained close to recent levels as investors positioned for the next quarterly update, with the shares trading near USD 63 through the latest sessions.
Price data from CNBC for the same session show that Bristol Myers Squibb closed at USD 63.06 on September 18, 2026, corresponding to a 0.35 percent advance from the prior close and placing the stock between its 52-week low of USD 42.53 and high of USD 68.64. The closing move compared with a modest gain in the Nasdaq Composite index on September 18, 2026, when the technology-heavy benchmark finished 0.39 percent higher, highlighting that Bristol Myers Squibb stock broadly kept pace with the wider equity market during the latest completed trading day.CNBC and TTV both documented the index performance for that date.
Today’s focus for Bristol Myers Squibb
Into today’s session on September 21, 2026, investors continue to watch Bristol Myers Squibb for developments around its pipeline and collaborations following recent trial and transaction news involving partner companies. As The Chosun Ilbo reported on September 21, 2026, Bristol Myers Squibb recently halted development of BMS-986497, a candidate treatment for acute myeloid leukemia, leading to the termination of an asset transfer agreement with Orum Therapeutics that had been signed in 2023, an outcome that has weighed on Orum’s shares in South Korea and may draw attention to Bristol Myers Squibb’s broader research strategy today.
In parallel, clinical progress in other areas remains in focus. A report published on September 21, 2026 by Familydoctor.cn highlighted that Bristol Myers Squibb’s oral CELMoD drug mezigdomide achieved positive phase 3 SUCCESSOR-2 trial results in relapsed or refractory multiple myeloma, meeting its primary endpoint of improved progression-free survival compared with a standard combination regimen. These contrasting signals from different parts of the company’s pipeline, together with a consensus price target around the mid-USD 60 range as noted by Mitrade on September 20, 2026, are likely to frame how Bristol Myers Squibb stock is discussed ahead of the New York opening bell today, even as the next formal quarterly update is expected in October rather than in the coming days.
